Frontida BioPharm, Inc.

Check out Dr. Eric Kinzler's captivating talk about new products for abuse deterrence. As Frontida's Cat.one study director, he is uniquely positioned to lead and develop novel abuse-deterrent products. Click on the link below.

https://www.youtube.com/watch?v=D01Ki5ayFyA

Frontida is a minority-owned CDMO specializing in pharmaceutical contract manufacturing. Our team of world-renowned scientists has spent decades creating immediate and modified-release oral dosages. Our priorities are efficiency and a reduction of production costs.

https://frontidabiopharm.com/about-us/

As a one-stop CDMO, Frontida is capable of developing and manufacturing oral solid dose products from beginning to end. With this in mind, we are also capable of taking your pre-established projects and tech transfer into our facilities. With our 325,000+ sq ft GMP facilities, located in Philadelphia, PA and Aurora, IL, we have the capacity to manufacture up to 3 billion units per year.

https://frontidabiopharm.com/pharmaceutical-manufacturing/

Syringeability is a common and dangerous method of abuse. Frontida's Cat.one testing assesses the ability to draw into and expel out of syringes with various needle gauges. Through injection studies, the API content in the expelled volume can be determined, and the solution’s viscosity can be assessed.
https://frontidabiopharm.com/cat-one-laboratory-testing-services/